Scarica l'app Stockscreener
9.51
2.36%
-0.23
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NXTC Giù?
Forum
Previsione
Precedente Chiudi:
$9.74
Aprire:
$10.07
Volume 24 ore:
6,928
Relative Volume:
0.15
Capitalizzazione di mercato:
$32.87M
Reddito:
-
Utile/perdita netta:
$-55.84M
Rapporto P/E:
-0.5405
EPS:
-17.5951
Flusso di cassa netto:
$-49.61M
1 W Prestazione:
-2.76%
1M Prestazione:
-7.89%
6M Prestazione:
-4.90%
1 anno Prestazione:
+2,071%
Intervallo 1D:
$9.10
$10.07
Intervallo di 1 settimana:
$9.10
$11.14
Portata 52W:
$0.39
$15.74
Nextcure Inc Stock (NXTC) Company Profile
Nome
Nextcure Inc
Settore
Industria
Telefono
240-399-4900
Indirizzo
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
9.10 | 35.18M | 0 | -55.84M | -49.61M | -17.60 |
VRTX
Vertex Pharmaceuticals Inc
|
431.29 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
625.81 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
788.97 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
289.08 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
142.93 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-07 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2022-11-04 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-03-05 | Aggiornamento | Truist | Hold → Buy |
| 2021-01-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-07-16 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-07-13 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-07-13 | Downgrade | SunTrust | Buy → Hold |
| 2020-06-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-05-26 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-03-24 | Iniziato | The Benchmark Company | Buy |
| 2020-03-02 | Iniziato | ROTH Capital | Buy |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-12-05 | Iniziato | Needham | Buy |
| 2019-11-26 | Iniziato | BTIG Research | Buy |
| 2019-07-09 | Iniziato | BofA/Merrill | Buy |
| 2019-06-03 | Iniziato | Morgan Stanley | Overweight |
| 2019-06-03 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Nextcure Inc Borsa (NXTC) Ultime notizie
NextCure stock (US65343E1082): biotech shares react to recent strategic update and Nasdaq trading mo - AD HOC NEWS
SilverArc and Devesh Gandhi report 176,057 shares in NextCure (NXTC) - Stock Titan
TradingKey - TradingKey
Lucid Capital Markets initiates NextCure stock with buy on ADC pipeline - Investing.com
Lucid Capital Markets initiates coverage of NextCure (NXTC) with buy recommendation - MSN
NXTC (NextCure) earnings beat estimates by 67 percent, yet shares retreat despite EPS outperformance.Attention Driven Stocks - newser.com
How NextCure (NXTC) maintains its competitive edge | Q4 2025: Profit Exceeds ViewsUpside Surprise - newser.com
NextCure | 10-Q: Quarterly report - Moomoo
NextCure 1Q Loss/Shr $1.87 >NXTC - Moomoo
NextCure | 10-Q: Q1 2026 Earnings Report - Moomoo
NextCure (NASDAQ: NXTC) narrows loss but warns on going-concern and funding needs - Stock Titan
NextCure | 8-K: NextCure Provides Business Update and Reports First Quarter 2026 Financial Results - Moomoo
FDA Fast Track and narrower loss mark Q1 2026 for NextCure (NASDAQ: NXTC) - Stock Titan
NextCure maps June cancer data, says cash lasts into 2027 - Stock Titan
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results - Weekly Voice
Simcere entities disclose 9.4% stake in NextCure (NXTC) - Stock Titan
NextCure initiates dose optimization study for ovarian cancer drug - Investing.com
NextCure initiates dose optimization study for ovarian cancer drug By Investing.com - Investing.com Nigeria
Biotechnology company NextCure Inc. announced it is accelerating the progress of its R&D projects by expanding its clinical research center network to Canada and Europe. - Bitget
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers - The Manila Times
NextCure moves ovarian cancer drug into dose testing before ASCO - Stock Titan
NextCure Inc expected to post a loss of $1.81 a shareEarnings Preview - TradingView
What capacity utilization NextCure (NXTC)? (-2.47%) 2026-04-27Crowd Consensus Signals - Newser
NextCure (NXTC) Stock Rejected Order (Smart Money Exits) 2026-04-24Top Analyst Picks - Newser
NextCure (NASDAQ: NXTC) plans 2026 meeting, auditor, pay and equity plan votes - Stock Titan
NextCure to present SIM0505 cancer drug data at ASCO meeting - Investing.com
NextCure to present SIM0505 cancer drug data at ASCO meeting By Investing.com - Investing.com South Africa
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026 - The Manila Times
NextCure and Simcere Announce Presentation of Phase 1 Data for SIM0505 at ASCO 2026 - Quiver Quantitative
NextCure Inc stock (US65343E1082): Is its immunotherapy pipeline strong enough to unlock biotech ups - AD HOC NEWS
Ladenburg Thalmann Upgrades NextCure (NXTC) - MSN
NXTC Forecast, Price Target & Analyst Ratings | NEXTCURE INC (NASDAQ:NXTC) - ChartMill
Resistance Check: Will Argan Inc benefit from rate cutsPortfolio Update Report & Risk Managed Trade Strategies - baoquankhu1.vn
GUOCHUN INTERNATIONAL INC. Reports No Revenue and Material Weaknesses in Q3 2025 10-Q/A Filing - Minichart
Published on: 2026-04-09 04:19:51 - baoquankhu1.vn
Surprises Report: Is NextCure Inc stock good for income investorsNew Guidance & Safe Entry Trade Signal Reports - baoquankhu1.vn
FDA Gives Fast Track Status to SIM0505 in Platinum-Resistant Ovarian Cancer - CancerNetwork
Activity Recap: Is NextCure Inc a defensive stock2026 News Drivers & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Is NextCure (NXTC) Stock heavily shorted | Price at $12.10, Up 8.67%Popular Trader Picks - newser.com
Value Recap: How is NextCure Inc managing supply chain issues2026 Geopolitical Influence & Verified Short-Term Plans - baoquankhu1.vn
NextCure Gets FDA Fast Track for SIM0505 in Ovarian Cancer - National Today
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer - Bitget
FDA fast-tracks NextCure ovarian cancer drug ahead of ASCO data - Stock Titan
Resistance Check: Is NextCure Inc exposed to currency risksMarket Performance Recap & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Trend Report: Will Investcorp Credit Management BDC Inc Preferred Security outperform tech stocksWeekly Investment Summary & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
NXTC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
Sacral Fracture Risk After Short-Course RT for Rectal Cancer - Medscape
NXTC Stock Analysis: NextCure Inc. Biotech Gains 1.80 Percent to 10.72 Support Level - newser.com
Buyout Rumor: Will American Tower Corporation stock go up in YEAR2026 Key Lessons & Stepwise Trade Signal Guides - baoquankhu1.vn
NXTC Should I Buy - Intellectia AI
Nextcure Inc Azioni (NXTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.44%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):